| | GAITHERSBURG, Md., May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference. | Conference Details: | | | | Fireside Chat | | | Date: | Thursday, June 6, 2024 | | Time: | 12:30 – 12:55 p.m. Eastern Time (ET) | | Location: | New York, NY | | Moderator: | Roger Song, MD, CFA, Equity Research Analyst – Biotechnology | | Novavax participant: | John C. Jacobs, President and Chief Executive Officer | | | | | | Conference | | | Event: | Investor Meetings | | Date: | Thursday, June 6, 2024 | Recordings
A replay of the recorded fireside session will be available through the Events & Presentations page of the Company’s website at ir.novavax.com for 30 days from the date of the conference. About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax’s patented Matrix-M adjuvant to enhance the immune response. The Company’s portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax’s adjuvant is included in the University of Oxford and Serum Institute of India’s R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information. Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com Media
Giovanna Chandler
240-720-7804
media@novavax.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-2024-jefferies-global-healthcare-conference-302158433.html
SOURCE Novavax, Inc. | |
